A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 38,044 shares of VRTX stock, worth $15.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
38,044
Previous 35,721 6.5%
Holding current value
$15.7 Million
Previous $16.7 Million 5.67%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$460.0 - $505.78 $1.07 Million - $1.17 Million
2,323 Added 6.5%
38,044 $17.7 Million
Q2 2024

Jul 19, 2024

BUY
$392.81 - $485.53 $2.29 Million - $2.83 Million
5,824 Added 19.48%
35,721 $16.7 Million
Q1 2024

Apr 22, 2024

BUY
$407.69 - $446.08 $1.63 Million - $1.78 Million
3,999 Added 15.44%
29,897 $12.5 Million
Q4 2023

Jan 16, 2024

BUY
$343.0 - $410.68 $332,024 - $397,538
968 Added 3.88%
25,898 $10.5 Million
Q3 2023

Oct 24, 2023

SELL
$338.18 - $362.46 $249,238 - $267,133
-737 Reduced 2.87%
24,930 $8.67 Million
Q2 2023

Jul 25, 2023

BUY
$314.42 - $351.91 $203,744 - $228,037
648 Added 2.59%
25,667 $9.03 Million
Q1 2023

Apr 14, 2023

SELL
$283.23 - $323.1 $1.21 Million - $1.38 Million
-4,257 Reduced 14.54%
25,019 $7.88 Million
Q4 2022

Feb 08, 2023

BUY
$285.76 - $321.48 $1.79 Million - $2.02 Million
6,273 Added 27.27%
29,276 $8.45 Million
Q3 2022

Oct 25, 2022

SELL
$273.83 - $305.53 $900,900 - $1.01 Million
-3,290 Reduced 12.51%
23,003 $6.66 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $66,493 - $82,791
-283 Reduced 1.06%
26,293 $7.41 Million
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $270,353 - $318,644
1,221 Added 4.82%
26,576 $6.94 Million
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $131,341 - $165,799
742 Added 3.01%
25,355 $5.57 Million
Q3 2021

Nov 02, 2021

BUY
$181.39 - $202.99 $734,085 - $821,500
4,047 Added 19.68%
24,613 $4.47 Million
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $491,036 - $579,060
2,619 Added 14.59%
20,566 $4.15 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $2.08 Million - $2.42 Million
-10,040 Reduced 35.87%
17,947 $3.86 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $1.6 Million - $2.14 Million
7,734 Added 38.19%
27,987 $6.61 Million
Q3 2020

Nov 04, 2020

SELL
$255.65 - $303.1 $3.48 Million - $4.13 Million
-13,614 Reduced 40.2%
20,253 $5.51 Million
Q2 2020

Jul 17, 2020

BUY
$225.48 - $295.8 $7.64 Million - $10 Million
33,867 New
33,867 $9.83 Million
Q1 2020

Apr 21, 2020

SELL
$199.77 - $247.81 $2.16 Million - $2.68 Million
-10,807 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$166.71 - $223.91 $173,211 - $232,642
-1,039 Reduced 8.77%
10,807 $2.37 Million
Q3 2019

Nov 07, 2019

SELL
$166.23 - $187.09 $2.98 Million - $3.35 Million
-17,901 Reduced 60.18%
11,846 $2.01 Million
Q2 2019

Aug 06, 2019

SELL
$164.61 - $190.37 $149,795 - $173,236
-910 Reduced 2.97%
29,747 $5.46 Million
Q1 2019

May 06, 2019

BUY
$163.73 - $194.7 $767,566 - $912,753
4,688 Added 18.05%
30,657 $5.64 Million
Q4 2018

Feb 11, 2019

SELL
$151.91 - $192.21 $1.36 Million - $1.73 Million
-8,978 Reduced 25.69%
25,969 $4.3 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $262,832 - $302,023
1,567 Added 4.69%
34,947 $6.74 Million
Q2 2018

Jul 30, 2018

BUY
$145.72 - $169.96 $143,679 - $167,580
986 Added 3.04%
33,380 $5.67 Million
Q1 2018

Apr 16, 2018

BUY
$151.6 - $177.13 $2.07 Million - $2.42 Million
13,681 Added 73.11%
32,394 $5.28 Million
Q4 2017

Feb 09, 2018

SELL
$137.28 - $155.55 $1.32 Million - $1.5 Million
-9,643 Reduced 34.01%
18,713 $2.8 Million
Q3 2017

Oct 26, 2017

BUY
$148.13 - $162.24 $3.24 Million - $3.55 Million
21,887 Added 338.34%
28,356 $4.31 Million
Q2 2017

Aug 15, 2017

BUY
N/A
6,469
6,469 $834,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $106B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.